Biogen Profit Beats Estimates on Tysabri Revenue Increase

Biogen Idec Inc., the fourth-largest U.S. biotechnology company by market value, reported first-quarter net income rose 41 percent on higher sales of its multiple sclerosis drugs.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.